The study also noted that the rapid rise in prescribing since 2020 coincided with the approval and PBS listing of semaglutide in Australia, which likely drove much of the recent increase
GLP-1 receptor agonists such as semaglutide and liraglutide are licensed for type 2 diabetes mellitus and, in specific formulations, for weight management in carefully selected patients meeting NICE criteria
Ruiz et al., 2015), 12 weeks (Forti et al., 2014), and as long as 9 months in individuals with type 2 diabetes (Swift et al., 2012) have not been shown to change basal serum BDNF
Side effects tend to be mild and transient
Huang F, Shen X, Zhang Y, Vuong AM, Yang S
The combination may result in more severe or prolonged gastrointestinal symptoms, potentially leading to dehydration, electrolyte imbalances, or nutritional deficiencies if food intake becomes severely restricted